Effects of adjunctive memantine on executive function and global cognition in bipolar disorder (BD): A randomized, double-blind, placebo-controlled clinical trial.

J Affect DisordJul 24, 2026 (epub)
Clinical ResearchPsychiatry

Hasan Mirzazadeh, Erfan Sadeghi, Sara Mostafavi et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized, double-blind, placebo-controlled trial assessed the effects of adjunctive memantine on cognitive function in 63 patients with bipolar I disorder receiving lithium and olanzapine. Results indicated that memantine significantly improved global cognition at week 6 (MD = 9.32) and week 18 (MD = 12.69), as well as executive function by week 18 (MD = 2.68).

Key findings

  • Memantine improved global cognition at week 6 (MD = 9.32; P < 0.001).
  • Global cognition improvement continued at week 18 (MD = 12.69; P < 0.001).
  • Executive function scores favored memantine at week 18 (MD = 2.68; P < 0.001).
  • Significant benefits were observed in attention, memory, and several FAB subscales by week 18.

Why it matters

Cognitive impairment is a significant issue in bipolar disorder, impacting patient quality of life. This study suggests that memantine may offer a pharmacological option to enhance cognitive function, potentially improving overall patient outcomes.

Source

PubMed · PMID 42498119

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.